Author Interview: Professor Atul Deodhar

Professor Atul Deodhar, professor of medicine at Oregon Health & Science University.

Discussing Rheumatology: Risk of HZ with UPA, and JAKs in SpA

Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis.

Author Interview: Professor Roy Fleischmann

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center.

Discussing Rheumatology: Herpes Zoster and HBV

Prof Iain McInnes discusses the risk of herpes zoster in RA patients taking biologics and DMARDS. He also discusses reactivation of hepatitis B in patients with RA taking tofacitinib.

Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness

Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy

Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.